<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Pharmacol Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Pharmacol. Rev</journal-id>
<journal-id journal-id-type="hwp">pharmrev</journal-id>
<journal-id journal-id-type="pmc">Pharmacol Rev</journal-id>
<journal-id journal-id-type="publisher-id">PharmRev</journal-id>
<journal-title-group>
<journal-title>Pharmacological Reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0031-6997</issn>
<issn pub-type="epub">1521-0081</issn>
<publisher>
<publisher-name>The American Society for Pharmacology and Experimental Therapeutics</publisher-name>
<publisher-loc>Bethesda, MD</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26408528</article-id>
<article-id pub-id-type="pmc">4630566</article-id>
<article-id pub-id-type="publisher-id">PHARMREV_010397</article-id>
<article-id pub-id-type="doi">10.1124/pr.114.010397</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Regulation of the Dopamine and Vesicular Monoamine Transporters: Pharmacological Targets and Implications for Disease</article-title>
<alt-title alt-title-type="short">DAT, VMAT2, Neurotoxicity, and Neuroprotection</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>German</surname>
<given-names>Christopher L.</given-names>
</name>
<xref ref-type="author-notes" rid="afn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baladi</surname>
<given-names>Michelle G.</given-names>
</name>
<xref ref-type="author-notes" rid="afn1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>McFadden</surname>
<given-names>Lisa M.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hanson</surname>
<given-names>Glen R.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Fleckenstein</surname>
<given-names>Annette E.</given-names>
</name>
</contrib>
<aff id="aff1">School of Dentistry (C.L.G., M.G.B., G.R.H., A.E.F.) and Department of Pharmacology and Toxicology (L.M.M., G.R.H.), University of Utah, Salt Lake City, Utah</aff>
</contrib-group>
<contrib-group>
<contrib contrib-type="editor">
<name>
<surname>Daws</surname>
<given-names>Lynette C.</given-names>
</name>
<role>ASSOCIATE EDITOR</role>
</contrib>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>Address correspondence to:</bold> Dr. Annette E. Fleckenstein, <addr-line>School of Dentistry, University of Utah, 530 Wakara Way, Salt Lake City, UT 84108.</addr-line> E-mail: <email>fleckenstein@hsc.utah.edu</email></corresp>
<fn fn-type="equal" id="afn1">
<label>1</label>
<p>C.L.G. and M.G.B. contributed equally as first authors.</p>
</fn>
</author-notes>
<pub-date pub-type="ppub">
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>1</day>
<month>10</month>
<year>2016</year>
</pub-date>
<!-- PMC Release delay is 12 months and
						0 days and was based on the <pub-date
						pub-type="ppub"/>. -->
<volume>67</volume>
<issue>4</issue>
<fpage>1005</fpage>
<lpage>1024</lpage>
<permissions>
<copyright-statement>Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics</copyright-statement>
<copyright-year>2015</copyright-year>
</permissions>
<self-uri xlink:href="pr.114.010397.pdf" xlink:title="pdf" xlink:type="simple"></self-uri>
<abstract>
<p>Dopamine (DA) plays a well recognized role in a variety of physiologic functions such as movement, cognition, mood, and reward. Consequently, many human disorders are due, in part, to dysfunctional dopaminergic systems, including Parkinson’s disease, attention deficit hyperactivity disorder, and substance abuse. Drugs that modify the DA system are clinically effective in treating symptoms of these diseases or are involved in their manifestation, implicating DA in their etiology. DA signaling and distribution are primarily modulated by the DA transporter (DAT) and by vesicular monoamine transporter (VMAT)-2, which transport DA into presynaptic terminals and synaptic vesicles, respectively. These transporters are regulated by complex processes such as phosphorylation, protein–protein interactions, and changes in intracellular localization. This review provides an overview of 1) the current understanding of DAT and VMAT2 neurobiology, including discussion of studies ranging from those conducted in vitro to those involving human subjects; 2) the role of these transporters in disease and how these transporters are affected by disease; and 3) and how selected drugs alter the function and expression of these transporters. Understanding the regulatory processes and the pathologic consequences of DAT and VMAT2 dysfunction underlies the evolution of therapeutic development for the treatment of DA-related disorders.</p>
</abstract>
<counts>
<page-count count="20"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name> DJS Export </meta-name>
<meta-value>v1</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>